MSN Labs unveils new drug for percutaneous coronary intervention
The drug reduces the risk of periprocedural myocardial infarction (MI), repeat coronary revascularisation, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor
image for illustrative purpose
Hyderabad: Hyderabad-based MSN Laboratories became the first company to launch the generic Canreal injection (Cangrelor) in India, indicated as an adjunct to percutaneous coronary intervention (PCI), also known as coronary angioplasty, a nonsurgical procedure that improves blood flow to heart.
The drug reduces the risk of periprocedural myocardial infarction (MI), repeat coronary revascularisation, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
The company said, the bioequivalent generic drug is the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition developed to overcome both delayed and prolonged anti platelet activity.
The drug was approved by DCGI (Drug Controller General of India) recognising the unmet need for intravenous rapidly acting, reversible antiplatelet agent in the country.
The company said, this launch signifies MSN Labs' commitment to bring access to new, affordable, and diverse therapeutic options, swiftly and consistently, for helping the world overcome life-threatening diseases.
The product which comes in a single-use 10 ml vial containing 50 mg Cangrelor as a lyophilised powder for reconstitution, is manufactured at FDA and EU approved state-of-the-art injectable facility in Hyderabad. The drug is available at all retail/hospital attached pharmaceutical outlets and is dispensed upon a prescription by a cardiologist.
